CJC-1295 without DAC (Mod GRF 1-29) paired with Ipamorelin is the most widely used growth hormone peptide protocol in the research community. The combination is popular for one specific reason: it produces significantly larger GH pulses than either peptide alone, using a clean, selective mechanism that avoids the cortisol, prolactin, and appetite side effects of older GHRPs. This guide covers exactly how the stack works, how to run it, and what research and community experience says about outcomes.
Research context only. The peptides discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
The CJC-1295 and Ipamorelin stack is the most popular GH peptide protocol. This guide covers how they work together, exact dosing, timing, cycling, and what to expect.
Why These Two Peptides Work Better Together
CJC-1295 (without DAC) and Ipamorelin work through completely different receptors on pituitary somatotroph cells. CJC-1295 is a GHRH analogue — it binds the GHRH receptor and amplifies the pituitary's readiness to release GH. Ipamorelin is a ghrelin mimetic — it binds the GHS-R1a receptor and directly triggers the GH release event. Using both simultaneously is like pressing both the accelerator and releasing the handbrake at the same time.
In pharmacological terms, the combination is synergistic rather than merely additive. Studies on combined GHRH and GHRP administration show GH pulses 3–5x larger than either compound alone, at equivalent doses. This is the core scientific rationale for the stack: maximum GH stimulation with selective, physiological mechanisms and minimal side effects.
Dosing, Timing, and Administration
Standard protocol: 100–300 mcg of each peptide (CJC-1295 and Ipamorelin) per injection, combined in the same syringe, administered subcutaneously. The two peptides can be reconstituted separately and then drawn into the same syringe for injection — they are chemically compatible and do not degrade each other.
Timing is critical and should be rigorously observed. Both peptides should be injected in a fasted state — minimum 2 hours since last meal, ideally longer. Elevated blood glucose blunts the GH pulse by stimulating somatostatin, which counteracts the GHRH and ghrelin receptor signals. Pre-sleep injection on an empty stomach is the highest-value dose, as it amplifies the natural GH pulse that occurs during early slow-wave sleep. A second injection upon waking (also fasted) is common in more intensive protocols.
Cycling, Side Effects, and Blood Monitoring
The standard cycle length is 8–12 weeks on, followed by 4–8 weeks off. The off period allows pituitary receptor sensitivity to normalise. Some long-term users report running 6-months-on / 2-months-off without apparent desensitisation, but the evidence base for long-cycle protocols is anecdotal.
Side effects are generally minimal with this stack. Water retention is the most common complaint — GH elevation promotes renal water and sodium retention, which typically resolves at dose reduction. Mild tingling or numbness in extremities (CTS-like) can occur at higher doses due to GH-mediated tissue swelling. Hunger increase is minimal compared to older GHRPs, though some users notice mild appetite stimulation.
Blood monitoring: IGF-1 is the most useful marker for gauging protocol efficacy and safety. GH itself is difficult to measure (pulsatile secretion), but IGF-1 reflects overall GH output and has a longer half-life. Target IGF-1 in the upper-normal range for age. Fasting glucose should be monitored in diabetic or pre-diabetic individuals as GH can cause transient insulin resistance.
CJC-1295 + Ipamorelin Dosing Reference
| Protocol | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| Starting dose | 100 mcg each | SubQ | Once daily pre-sleep | Assess response before escalating |
| Standard dose | 200 mcg each | SubQ | Once daily pre-sleep | Most common effective dose |
| Intensive dose | 200–300 mcg each | SubQ | Twice daily (AM fasted + pre-sleep) | For accelerated body recomposition |
| CJC-1295 alone | 100–200 mcg | SubQ | Once daily | If Ipamorelin unavailable |
| Ipamorelin alone | 200–300 mcg | SubQ | Once daily pre-sleep | Cleaner; less potent than combo |
Research-Grade Sourcing
WolveStack partners with Ascension Peptides for independently third-party tested research compounds with published COAs. The links below go directly to the relevant products.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Also Available at Apollo Peptide Sciences
Apollo Peptide Sciences carries independently tested research-grade compounds. Products ship from the USA with published purity certificates.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Complete Guide
CJC-1295 : Benefits, Dosage, Side Effects & Research
Frequently Asked Questions
They should be injected at the same time but can be in separate syringes. The reason for simultaneous injection is that their complementary mechanisms produce a synergistic GH pulse when both receptors are activated at the same time. Injecting them hours apart reduces the synergistic benefit. They can be drawn into the same syringe and injected together — this is the most convenient approach.
Sleep quality improvements are often noticed within the first 1–2 weeks. Recovery changes (faster muscle soreness resolution, better joint comfort) typically appear at 3–6 weeks. Body composition changes — visible reduction in body fat and modest improvement in muscle fullness — take 8–12 weeks of consistent use to become apparent. IGF-1 levels measurably elevate within 2–4 weeks.
CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of about 30 minutes — it produces a discrete GH pulse mimicking the natural pulsatile pattern. CJC-1295 with DAC has a half-life of 6–8 days due to a drug affinity complex modification — it produces sustained, blunted GH elevation rather than a pulse. The stack uses the without-DAC version because pulsatile GH release is more physiological and produces better receptor sensitivity long-term.
Yes — GH secretagogues are used by women and the mechanisms are sex-independent. Women naturally have higher baseline GH secretion than men, so lower doses (100 mcg each) are typically sufficient to produce meaningful GH amplification. The same fasting protocols and timing apply. Monitoring IGF-1 is particularly useful in women to confirm appropriate dose calibration.
MK-677 (Ibutamoren) is an oral ghrelin mimetic that works through the same receptor as Ipamorelin — it is the oral alternative. Advantages: no injections, convenient, and it sustains IGF-1 elevation throughout the day. Disadvantages: blunted rather than pulsatile GH release, significant appetite stimulation, potential water retention, and the sustained GH elevation may cause more insulin resistance than pulsatile protocols. The injectable stack is more physiological; MK-677 is more convenient.